Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.

Item
http://www.wikidata.org/entity/Q34344198
Quantification of HER family receptors in breast cancerEfficacy and safety of dose-dense chemotherapy in urothelial carcinoma.The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancerHER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network.Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.Resistance to Targeted Therapies in Breast Cancer.The assessment of HER2 status in breast cancer: the past, the present, and the future.Predictive factors of pathologic complete response of HER2-positive breast cancer after preoperative chemotherapy with trastuzumab: development of a specific predictor and study of its utilities using decision curve analysis.Counting invasive breast cancer cells in the HER2 silver in-situ hybridization test: how many cells are enough?Clinical and Molecular Methods in Drug Development: Neoadjuvant Systemic Therapy in Breast Cancer as a Model.Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.Low frequency of HER2 amplification and overexpression in early onset gastric cancer.Clinical significance of quantitative HER2 gene amplification as related to its predictive value in breast cancer patients in neoadjuvant setting.Relationship between gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatmentIntratumor heterogeneity defines treatment-resistant HER2+ breast tumors
P2860

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.

Item
http://www.wikidata.org/entity/Q34344198
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pathological complete response ...... ant therapy for breast cancer.
@ast
Pathological complete response ...... ant therapy for breast cancer.
@en
Pathological complete response ...... ant therapy for breast cancer.
@nl
type
label
Pathological complete response ...... ant therapy for breast cancer.
@ast
Pathological complete response ...... ant therapy for breast cancer.
@en
Pathological complete response ...... ant therapy for breast cancer.
@nl
prefLabel
Pathological complete response ...... ant therapy for breast cancer.
@ast
Pathological complete response ...... ant therapy for breast cancer.
@en
Pathological complete response ...... ant therapy for breast cancer.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P6179
P698
P932
P356
P1433
P1476
Pathological complete response ...... ant therapy for breast cancer.
@en
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P50
P577
P5875
P6179
P698
P932